PLRX - Pliant Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
PLRX price evolution
PLRX
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $44.62 | $25.07 | $32.55 | $51.66 |
| Short term investments | $315.62 | $138.53 | $145.74 | $148.93 |
| Net receivables | $1.48 | $4.99 | $1.25 | $2 |
| Inventory | ||||
| Total current assets | $365.96 | $173.53 | $185.36 | $209.44 |
| Long term investments | ||||
| Property, plant & equipment | $10.82 | $10.18 | $10.82 | $10.94 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.22 | $11.09 | $11.66 | $11.77 |
| Total investments | $315.62 | $138.53 | $145.74 | $148.93 |
| Total assets | $377.18 | $184.62 | $197.02 | $221.22 |
| Current liabilities | ||||
| Accounts payable | $3.21 | $3.12 | $4.68 | $2.97 |
| Deferred revenue | ||||
| Short long term debt | $2.65 | $2.04 | $2 | $1.87 |
| Total current liabilities | $26.16 | $22.55 | $18.31 | $16.83 |
| Long term debt | $14.03 | $14.28 | $4.92 | $5.33 |
| Total noncurrent liabilities | $14.03 | $14.28 | $4.92 | $5.33 |
| Total debt | $16.68 | $16.32 | $6.92 | $7.19 |
| Total liabilities | $40.19 | $36.83 | $23.23 | $22.16 |
| Shareholders' equity | ||||
| Retained earnings | -$303.35 | -$272.74 | -$243.19 | -$215.09 |
| Other shareholder equity | -$2.45 | -$1.26 | -$0.95 | -$0.2 |
| Total shareholder equity | $336.99 | $147.79 | $173.79 | $199.06 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Jan 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $51.66 | $50.88 | $85.81 | $60.95 |
| Short term investments | $148.93 | $226.01 | $16.97 | |
| Net receivables | $2 | $9.28 | $7.05 | $0.5 |
| Inventory | ||||
| Total current assets | $209.44 | $290.75 | $111.9 | $61.73 |
| Long term investments | ||||
| Property, plant & equipment | $10.94 | $4.32 | $4.08 | $4.26 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $11.77 | $4.77 | $7.16 | $4.8 |
| Total investments | $148.93 | $226.01 | $16.97 | |
| Total assets | $221.22 | $295.53 | $119.06 | $66.53 |
| Current liabilities | ||||
| Accounts payable | $2.97 | $2.02 | $1.25 | $2.58 |
| Deferred revenue | ||||
| Short long term debt | $1.87 | |||
| Total current liabilities | $16.83 | $11.6 | $8.17 | $5.08 |
| Long term debt | $5.33 | |||
| Total noncurrent liabilities | $5.33 | $0.87 | $0.91 | $0.81 |
| Total debt | $7.19 | |||
| Total liabilities | $22.16 | $12.46 | $9.08 | $5.89 |
| Shareholders' equity | ||||
| Retained earnings | -$215.09 | -$117.83 | -$76.3 | -$71.47 |
| Other shareholder equity | -$0.2 | -$0.03 | -$0 | $132.1 |
| Total shareholder equity | $199.06 | $283.06 | -$76.3 | |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.48 | $4.99 | $1.25 | $2 |
| Cost of revenue | ||||
| Gross Profit | $1.48 | $4.99 | $1.25 | $2 |
| Operating activities | ||||
| Research & development | $24.61 | $26.34 | $20.88 | $18.75 |
| Selling, general & administrative | $8.82 | $8.3 | $8.58 | $7.85 |
| Total operating expenses | $33.43 | $34.63 | $29.46 | $26.6 |
| Operating income | -$31.95 | -$29.64 | -$28.21 | -$24.6 |
| Income from continuing operations | ||||
| EBIT | -$30.61 | -$29.55 | -$28.1 | -$24.53 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$30.61 | -$29.55 | -$28.1 | -$24.53 |
| Income (for common shares) | -$30.61 | -$29.55 | -$28.1 | -$24.53 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.57 | $41.82 | $57.05 | |
| Cost of revenue | ||||
| Gross Profit | $7.57 | $41.82 | $57.05 | |
| Operating activities | ||||
| Research & development | $77.55 | $66.19 | $47.35 | |
| Selling, general & administrative | $27.56 | $17.27 | $10.93 | |
| Total operating expenses | $105.11 | $83.46 | $58.28 | $30.91 |
| Operating income | -$97.53 | -$41.65 | -$1.23 | -$30.91 |
| Income from continuing operations | ||||
| EBIT | -$97.26 | -$41.53 | -$0.63 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$97.26 | -$41.53 | -$0.63 | -$30.28 |
| Income (for common shares) | -$97.26 | -$41.53 | -$6.86 | |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$30.61 | -$29.55 | -$28.1 | -$24.53 |
| Operating activities | ||||
| Depreciation | $1.03 | $0.9 | $0.7 | $2.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.81 | $3.4 | $3.53 | $2.77 |
| Total cash flows from operations | -$18.5 | -$24.4 | -$20.5 | -$19.86 |
| Investing activities | ||||
| Capital expenditures | -$0.7 | -$0.25 | -$0.64 | -$0.59 |
| Investments | -$177.56 | $6.75 | $2.17 | $26.38 |
| Total cash flows from investing | -$178.25 | $6.5 | $1.53 | $25.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $217.01 | $0.45 | $0.05 | $0.54 |
| Net borrowings | $9.85 | |||
| Total cash flows from financing | $216.3 | $10.43 | -$0.15 | $0.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $19.55 | -$7.47 | -$19.12 | $6.43 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$97.26 | -$41.53 | -$0.63 | -$30.28 |
| Operating activities | ||||
| Depreciation | $3.2 | $1.31 | $1.11 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.44 | $3.9 | $1.83 | |
| Total cash flows from operations | -$75.44 | -$37.27 | -$2.75 | -$28.33 |
| Investing activities | ||||
| Capital expenditures | -$1.95 | -$1.53 | -$0.96 | |
| Investments | $75.65 | -$209.33 | -$16.71 | |
| Total cash flows from investing | $73.7 | -$210.87 | -$17.93 | -$2.32 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.98 | $161.19 | $0.17 | |
| Net borrowings | ||||
| Total cash flows from financing | $2.53 | $213.21 | $45.54 | $87.35 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.78 | -$34.92 | $24.86 | $56.7 |
News
Fundamentals
| Market cap | $1.59B |
|---|---|
| Enterprise value | $1.56B |
| Shares outstanding | 48.75M |
| Revenue | $9.72M |
|---|---|
| EBITDA | -$108.08M |
| EBIT | -$112.79M |
| Net Income | -$112.79M |
| Revenue Q/Q | -7.95% |
| Revenue Y/Y | -3.18% |
| P/E ratio | -14.09 |
|---|---|
| EV/Sales | 160.69 |
| EV/EBITDA | -14.45 |
| EV/EBIT | -13.85 |
| P/S ratio | 163.57 |
| P/B ratio | 4.68 |
| Book/Share | 6.96 |
| Cash/Share | 0.92 |
| EPS | -$2.31 |
|---|---|
| ROA | -46.04% |
| ROE | -52.61% |
| Debt/Equity | 0.11 |
|---|---|
| Net debt/EBITDA | 0.04 |
| Current ratio | 13.99 |
| Quick ratio | 13.99 |